Asterand's PhaseZERO® Drug Discovery Services platform utilises human tissues in vitro to generate data that drive target validation and support decision making for progressing the best targets.
The services we provide apply across a range of different therapeutic research areas. Click here to download a summary of which PhaseZERO® services can be accessed within your therapeutic area of interest.
We aim to provide data to support the validation of human targets and biomarkers to facilitate selection of those with the greatest likelihood of clinical success.
Our human tissue-based approach allows rapid and early evaluation of targets and biomarkers in biologically relevant tissues to:
For over ten years our scientists have been consulted by and have collaborated with top, global pharmaceutical companies. We help our customers evaluate human targets and biomarkers, providing expertise and a tailored scientific approach to deliver high quality human tissue-based data.
We provide a wide range of standard and custom assays in the following areas:
The search for novel therapies to treat human disease often begins with the identification of viable drug targets via understanding gene expression differences between diseased and non-diseased tissues.
To support this understanding, Asterand offers four qRT-PCR-based services to validate human targets at the gene expression level:
Quantitative gene expression profiles to identify which non-diseased human tissues express a given target. Data are used to confirm therapeutic approach, exploit opportunities to switch indication and identify the potential for side effects.
A comprehensive database of expression of gene transcripts in non-diseased human tissues, together with proprietary software that will provides an interface to the information found in gene expression profiles, assisting in confirming, altering or negating pathway opportunities for your targets of choice.
A powerful follow-on capability to initial gene expression observations, focusing on targets of interest, to understand differential expression in any diseased and non-diseased tissue.
To further understand the potential function of a human target and its possible role in disease, it is important to localise that target at the cellular level. To achieve this, Asterand provides five core services:
In situ hybridisation (ISH)
Cellular localisation of target genes in human diseased and non-diseased tissues using high quality frozen human tissue sections or tissue microarrays.
Cellular localisation of target proteins in human diseased and non-diseased tissues using high quality FFPE or frozen human tissue sections or microarrays.
An IHC assay which assesses the cross-reactivity of therapeutic antibody candidates under non-GLP conditions in a frozen tissue microarray for customers screening antibody candidates prior to the comprehensive GLP study.
Combination of gene expression intelligence and IHC immunostaining to produce the highest quality digital photomicrographs of the research antibody’s immunoreactivity along with data regarding the optimum conditions for end user application of the antibody.
Localization of ligand binding sites in frozen human tissue sections. These studies allow you to: